However, after adjusting available clinical characteristics (age at diagnosis, stage, grade, and Ki‐67) and primary treatments (endocrine therapy, chemotherapy, and radiotherapy), HER2‐low BC showed significantly lower mortality than HER2‐zero BC among HR‐negative BC, with a hazard ratio of 0.69 (95%CI: 0.50–0.97, p = 0.031) (Figure 1, Table S3). Here, ERBB2 is linked to breast cancer.